Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2009

01.12.2009 | Hepatobiliary Tumors

Long-Term Results of Hepatic Resection Combined with Intraoperative Local Ablation Therapy for Patients with Multinodular Hepatocellular Carcinomas

verfasst von: Shinji Itoh, MD, PhD, Kazutoyo Morita, MD, Shigeru Ueda, MD, Keishi Sugimachi, MD, PhD, Yo-ichi Yamashita, MD, PhD, Tomonobu Gion, MD, PhD, Kengo Fukuzawa, MD, PhD, Kenzo Wakasugi, MD, PhD, Akinobu Taketomi, MD, PhD, Yoshihiko Maehara, MD, PhD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Recently, local ablation therapy has been widely used for treatment of small hepatocellular carcinoma (HCC). The present study assessed the outcome of hepatic resection combined with intraoperative local ablation therapy in patients with multinodular HCCs.

Methods

Forty-one patients with initial and multinodular HCCs underwent hepatic resection combined with intraoperative local ablation therapy. The mean maximum diameter of all tumors was 3.8 cm (range 2.1–16.0 cm), and the mean number of nodules was 3.2 (range 2–11). We evaluated the survival rates and assessed the prognostic factors associated with overall survival rates using Cox proportional hazard models.

Results

Intraoperative local ablation therapy was completed in all patients with no evidence of residual viable tumor on the first postoperative computed tomography (CT) scan. The 3-, 5- and 7-year overall survival rates were 84.3%, 61.2%, and 61.2%, respectively. Patients with preoperative des-gamma carboxyprothrombin (DCP) level >300 mAU/ml showed significantly worse overall survival than those with DCP level ≤300 mAU/ml (P < 0.01).

Conclusions

Hepatic resection combined with intraoperative local ablation therapy is effective for multinodular HCCs. DCP >300 mAU/ml was a significant prognostic factor of long-term overall survival.
Literatur
1.
Zurück zum Zitat Shimada M, Takenaka K, Fujiwara Y, et al. Risk factors linked to postoperative morbidity in patients with hepatocellular carcinoma. Br J Surg. 1998;85:195–8.CrossRefPubMed Shimada M, Takenaka K, Fujiwara Y, et al. Risk factors linked to postoperative morbidity in patients with hepatocellular carcinoma. Br J Surg. 1998;85:195–8.CrossRefPubMed
2.
Zurück zum Zitat Taketomi A, Kitagawa D, Itoh S, et al. Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute’s experience with 625 patients. J Am Coll Surg. 2007;204(4): 580–7.CrossRefPubMed Taketomi A, Kitagawa D, Itoh S, et al. Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute’s experience with 625 patients. J Am Coll Surg. 2007;204(4): 580–7.CrossRefPubMed
3.
Zurück zum Zitat Takenaka K, Kawahara N, Yamamoto K, et al. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg. 1996;131:71–6.PubMed Takenaka K, Kawahara N, Yamamoto K, et al. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg. 1996;131:71–6.PubMed
4.
Zurück zum Zitat Yamashita Y-i, Taketomi A, Itoh S, et al. Longterm favorable results of limited hepatic resections for patients with hepatocellular carcinoma. J Am Coll Surg. 2007;205(1):19–26.CrossRefPubMed Yamashita Y-i, Taketomi A, Itoh S, et al. Longterm favorable results of limited hepatic resections for patients with hepatocellular carcinoma. J Am Coll Surg. 2007;205(1):19–26.CrossRefPubMed
5.
Zurück zum Zitat Liver Cancer Study Group of Japan. Primary liver cancers in Japan. Cancer. 1980;45:2663–9.CrossRef Liver Cancer Study Group of Japan. Primary liver cancers in Japan. Cancer. 1980;45:2663–9.CrossRef
6.
Zurück zum Zitat Lai EC, Fan ST, Lo CM, et al. Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg. 1995;221:291–8.CrossRefPubMed Lai EC, Fan ST, Lo CM, et al. Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg. 1995;221:291–8.CrossRefPubMed
7.
Zurück zum Zitat Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma. Experience in Japan. Ann Surg. 2004;240:451–61.CrossRefPubMed Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma. Experience in Japan. Ann Surg. 2004;240:451–61.CrossRefPubMed
8.
Zurück zum Zitat Taketomi A, Soejima Y, Yoshizumi T, et al. Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2008;15:124–30.CrossRefPubMed Taketomi A, Soejima Y, Yoshizumi T, et al. Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2008;15:124–30.CrossRefPubMed
9.
Zurück zum Zitat Kudo M. Local ablation therapy for hepatocellular carcinoma: current status and future prospectives. J Gastroenterol. 2004;39(3): 205–14.CrossRefPubMed Kudo M. Local ablation therapy for hepatocellular carcinoma: current status and future prospectives. J Gastroenterol. 2004;39(3): 205–14.CrossRefPubMed
10.
Zurück zum Zitat Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004:40: 1352–60.CrossRefPubMed Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004:40: 1352–60.CrossRefPubMed
11.
Zurück zum Zitat Coinaud C. Lobes et segments hepatiques. Press Med. 1954;62: 709–12. Coinaud C. Lobes et segments hepatiques. Press Med. 1954;62: 709–12.
12.
Zurück zum Zitat Shimada M, Takenaka K, Taguchi K, et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg. 1998;227:80–5.CrossRefPubMed Shimada M, Takenaka K, Taguchi K, et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg. 1998;227:80–5.CrossRefPubMed
13.
Zurück zum Zitat Kanematsu T, Furuta T, Takenaka K, et al. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology. 1989;10:98–102.CrossRefPubMed Kanematsu T, Furuta T, Takenaka K, et al. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology. 1989;10:98–102.CrossRefPubMed
14.
Zurück zum Zitat Itoh S, Taketomi A, Tanaka S, et al. Role of growth factor receptor-bound protein 7 in hepatocellular carcinoma. Mol Cancer Res. 2007;5:667–73.CrossRefPubMed Itoh S, Taketomi A, Tanaka S, et al. Role of growth factor receptor-bound protein 7 in hepatocellular carcinoma. Mol Cancer Res. 2007;5:667–73.CrossRefPubMed
15.
Zurück zum Zitat Mazzafero V, Regalia E, Doci R, et al. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;14:728. Mazzafero V, Regalia E, Doci R, et al. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;14:728.
16.
Zurück zum Zitat Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462–503.CrossRefPubMed Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462–503.CrossRefPubMed
17.
Zurück zum Zitat Itoh S, Maeda T, Shimada M, et al. Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res. 2004;10:2812–7.CrossRefPubMed Itoh S, Maeda T, Shimada M, et al. Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res. 2004;10:2812–7.CrossRefPubMed
18.
Zurück zum Zitat Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201–9.CrossRefPubMed Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201–9.CrossRefPubMed
19.
Zurück zum Zitat Seki T, Wakabayashi M, Nakagawa T, et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. Cancer. 1999;85:1694–702.CrossRefPubMed Seki T, Wakabayashi M, Nakagawa T, et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. Cancer. 1999;85:1694–702.CrossRefPubMed
20.
Zurück zum Zitat Santambrogio R, Opocher E, Costa M, et al. Survival and intra-hepatic recurrences after laparoscopic radiofrequency of hepatocellular carcinoma in patients with cirrhosis. J Surg Oncol. 2005;89:218–25.CrossRefPubMed Santambrogio R, Opocher E, Costa M, et al. Survival and intra-hepatic recurrences after laparoscopic radiofrequency of hepatocellular carcinoma in patients with cirrhosis. J Surg Oncol. 2005;89:218–25.CrossRefPubMed
21.
Zurück zum Zitat Kawamoto C, Ido K, Isoda N, et al. Long-term outcomes for patients with solitary hepatocellular carcinoma treated by laparoscopic microwave coagulation. Cancer. 2005;103:985–93.CrossRefPubMed Kawamoto C, Ido K, Isoda N, et al. Long-term outcomes for patients with solitary hepatocellular carcinoma treated by laparoscopic microwave coagulation. Cancer. 2005;103:985–93.CrossRefPubMed
22.
Zurück zum Zitat Raut CP, Izzo F, Marra P, et al. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005;12:616–28.CrossRefPubMed Raut CP, Izzo F, Marra P, et al. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005;12:616–28.CrossRefPubMed
23.
Zurück zum Zitat Choi D, Lim HK, Joh JW, et al. Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol. 2007;14:3510–8.CrossRefPubMed Choi D, Lim HK, Joh JW, et al. Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol. 2007;14:3510–8.CrossRefPubMed
24.
Zurück zum Zitat Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229:790–800.CrossRefPubMed Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229:790–800.CrossRefPubMed
25.
Zurück zum Zitat Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-size hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224–9.CrossRefPubMed Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-size hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224–9.CrossRefPubMed
26.
Zurück zum Zitat Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol. 1995;22:522–6.CrossRefPubMed Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol. 1995;22:522–6.CrossRefPubMed
27.
Zurück zum Zitat Urata K, Matsumata T, Kamakura T, et al. Lipiodolization for unresectable hepatocellular carcinoma: An analysis of 205 patients using univariate and multivariate analysis. J Surg Oncol. 1994;56:54–8.CrossRefPubMed Urata K, Matsumata T, Kamakura T, et al. Lipiodolization for unresectable hepatocellular carcinoma: An analysis of 205 patients using univariate and multivariate analysis. J Surg Oncol. 1994;56:54–8.CrossRefPubMed
28.
Zurück zum Zitat The Liver Cancer Study Group of Japan. The general rules for clinical and pathological study of primary liver cancer, 4th ed. Tokyo: Kanehara; 2000. The Liver Cancer Study Group of Japan. The general rules for clinical and pathological study of primary liver cancer, 4th ed. Tokyo: Kanehara; 2000.
29.
Zurück zum Zitat Vivarelli M, Guglielmi A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240:102–7.CrossRefPubMed Vivarelli M, Guglielmi A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240:102–7.CrossRefPubMed
30.
Zurück zum Zitat Wakai T, Shirai Y, Suda T, et al. Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma ≤4 cm. World J Gastroenterol. 2006;12:546–52.PubMed Wakai T, Shirai Y, Suda T, et al. Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma ≤4 cm. World J Gastroenterol. 2006;12:546–52.PubMed
31.
Zurück zum Zitat Makuuchi M, Hasegawa H, Yamazaki S, et al. The use of operative ultrasound as an aid to liver resection in patients with hepatocellular carcinoma. World J Surg. 1987;11:615–21.CrossRefPubMed Makuuchi M, Hasegawa H, Yamazaki S, et al. The use of operative ultrasound as an aid to liver resection in patients with hepatocellular carcinoma. World J Surg. 1987;11:615–21.CrossRefPubMed
32.
Zurück zum Zitat Scaife CL, Ng CS, Ellis LM, et al. Accuracy of preoperative imaging of hepatic tumors with helical computed tomography. Ann Surg Oncol. 2006;13:542–6.CrossRefPubMed Scaife CL, Ng CS, Ellis LM, et al. Accuracy of preoperative imaging of hepatic tumors with helical computed tomography. Ann Surg Oncol. 2006;13:542–6.CrossRefPubMed
33.
Zurück zum Zitat The Liver Cancer Study Group of Japan. Predictive factors for long-term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer. 1994;74:2772–80.CrossRef The Liver Cancer Study Group of Japan. Predictive factors for long-term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer. 1994;74:2772–80.CrossRef
34.
Zurück zum Zitat Shimada M, Yamashita Y, Hamatsu T, et al. The role of des-gamma-carboxy prothrombin levels in hepatocellular carcinoma and liver tissues. Cancer Lett. 2000;159:87–94.CrossRefPubMed Shimada M, Yamashita Y, Hamatsu T, et al. The role of des-gamma-carboxy prothrombin levels in hepatocellular carcinoma and liver tissues. Cancer Lett. 2000;159:87–94.CrossRefPubMed
35.
Zurück zum Zitat Marrero JA, SuGL, Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37:1114–21.CrossRefPubMed Marrero JA, SuGL, Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37:1114–21.CrossRefPubMed
36.
Zurück zum Zitat Shimada M, Takenaka K, Fujiwara Y, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer. 1996;78:2094–100.CrossRefPubMed Shimada M, Takenaka K, Fujiwara Y, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer. 1996;78:2094–100.CrossRefPubMed
37.
Zurück zum Zitat Shirabe K, Itoh S, Yoshizumi T, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol. 2007;95:235–40.CrossRefPubMed Shirabe K, Itoh S, Yoshizumi T, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol. 2007;95:235–40.CrossRefPubMed
38.
Zurück zum Zitat Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561–9.CrossRefPubMed Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561–9.CrossRefPubMed
39.
Zurück zum Zitat Soejima Y, Taketomi A, Yoshizumi T, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation. 2007;83:893–9.CrossRefPubMed Soejima Y, Taketomi A, Yoshizumi T, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation. 2007;83:893–9.CrossRefPubMed
40.
Zurück zum Zitat Taketomi A, Sanefuji K, Soejima Y et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531–7.CrossRefPubMed Taketomi A, Sanefuji K, Soejima Y et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531–7.CrossRefPubMed
41.
Zurück zum Zitat Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007;13:1637–44.CrossRefPubMed Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007;13:1637–44.CrossRefPubMed
Metadaten
Titel
Long-Term Results of Hepatic Resection Combined with Intraoperative Local Ablation Therapy for Patients with Multinodular Hepatocellular Carcinomas
verfasst von
Shinji Itoh, MD, PhD
Kazutoyo Morita, MD
Shigeru Ueda, MD
Keishi Sugimachi, MD, PhD
Yo-ichi Yamashita, MD, PhD
Tomonobu Gion, MD, PhD
Kengo Fukuzawa, MD, PhD
Kenzo Wakasugi, MD, PhD
Akinobu Taketomi, MD, PhD
Yoshihiko Maehara, MD, PhD, FACS
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0721-0

Weitere Artikel der Ausgabe 12/2009

Annals of Surgical Oncology 12/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.